SCHEMBL2825935

SCHEMBL2825935

CC(C)(C)OC(=O)N1CCC[C@H](NC(=O)Nc2ccc(F)cc2)C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.64
FPR2 P25090 4/20 0.55
FPR3 P25089 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
EPHX1 P07099 2/20 0.55
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
EPHX2 P34913 1/20 0.52
RECQL P46063 1/20 0.51
HDAC4 P56524 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN6 P29350 1/20 0.48
KDM5B Q9UGL1 1/20 0.48
ABL1 P00519 1/20 0.47
RIN1 Q13671 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825936 1.00 USP30 (0.64) USP30FPR2FPR3NPC1RAB9A
SCHEMBL2955532 0.86 CA12 (0.70) FPR2NPC1RAB9AEPHX1CA12
SCHEMBL889030 0.82 FPR2 (0.67) USP30FPR2FPR3NPC1RAB9A
SCHEMBL26554653 0.82 CA12 (0.61) USP30FPR2FPR3NPC1RAB9A
SCHEMBL193294 0.82 RAB9A (0.65) NPC1RAB9APTPN2PTPN1PTPN6
SCHEMBL193295 0.82 RAB9A (0.65) NPC1RAB9APTPN2PTPN1PTPN6
SCHEMBL23555724 0.82 EPHX1 (0.69) USP30FPR2FPR3EPHX1CA12
SCHEMBL25153789 0.81 EPHX2 (0.70) EPHX1CA12CA1CA2CA9
SCHEMBL2825567 0.81 NPC1 (0.61) NPC1RAB9AEPHX1EPHX2RECQL
SCHEMBL2825568 0.81 NPC1 (0.61) NPC1RAB9AEPHX1EPHX2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893200-B1 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2010-09-29 EP disclosed
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2009-03-26 US disclosed
EP-1893200-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-03-05 EP disclosed
WO-2006123244-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors GRM5, GRIK5, GRM1 USP30 807/4885FPR2 1397/4885FPR3 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.